PDMP Workshops

Download a 29-page Preview Guide (pdf) to the 2013 National Rx Drug Abuse Summit.
 

Part 1 – New PDMP Developments / Thursday, April 4, 2013, 8:30 am – 9:30 am
Moderator	John L. Eadie Director, Prescription Monitoring Program Center of Excellence, Brandeis University
Presenters	Marty Allain Director, INSPECT     Josh Bolin Government Affairs Director, National Association of Boards of Pharmacy   LCDR Christopher M. Jones, PharmD, MPH Prescription Drug Overdose Team, Division of Unintentional Injury Prevention, Centers for Disease Control and Prevention
Description	According to the National Alliance for Model State Drug Laws (NAMSDL), in 2004, only 22 states had enacted legislation to implement a Prescription Drug Monitoring Program (PDMP). By 2010, the number of states with PDMP laws rose to 42. Today, every state except one has enacted legislation to implement a Prescription Drug Monitoring Program (PDMP). However, these programs must continue to evolve in order to enhance access to data and assist clinicians in reducing prescription drug abuse. In this session, we will discuss the new PDMP developments that are currently underway to integrate data and the impact these laws are having on prescribing practices and the prescription drug abuse issue.
Learning Objectives	1. Explain a Prescription Drug Monitoring Program (PDMP) 2. Investigate the efficiency and effectiveness of state-level programs to make improvements. 3. Outline strategies to enhance collaborations with law enforcement, prosecutors, treatment professionals, the medical community, pharmacies, and regulatory boards to establish a comprehensive PDMP strategy.
Part 2 – New Focuses for PDMP’s Efforts / Thursday, April 4, 2013, 9:45 am – 10:45 am
Moderator	John L. Eadie Director, Prescription Monitoring Program Center of Excellence, Brandeis University
Presenters	Jennifer Frazier Health Policy Analyst, Department of Health and Human Services     CDR Jinhee Lee Public Health Advisor, Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, SAMHSA     Mike Small Department of Justice Administrator II, California Department of Justice     Len Young Epidemiologist, Massachusetts Department of Public Health
Description	As each state adopts their own version of the PDMP, opportunities for new focuses for PDMPs must be undertaken in order to increase the effectiveness of these programs. This session will outline best practices for the PDMP to notify prescribers who are frequently visited by doctor shoppers. We will also discuss the evaluation of high volume prescribers and deaths of patients by the media.
Learning Objectives	1. Outline strategies to enhance existing programs’ abilities to analyze and use collected data to identify drug abuse trends. 2. Explain how to enhance existing programs’ ability to analyze and use collected data. 3. Outline new opportunities for PDMP to effectively identify doctor shoppers.
Part 3 – PDMP Coordination with Third-Party Payers / Thursday, April 4, 2013, 11:00 am – Noon
Moderator	John L. Eadie Director, Prescription Monitoring Program Center of Excellence, Brandeis University
Presenters	Chris Baumgartner PMP Director, Washington State Prescription Drug Monitoring Program   Alex Swedlow Executive Vice President, Research, California Workers’ Compensation Institute   Bruce C. Wood Associate General Counsel and Director, Workers’ Compensation, American Insurance Association
Description	Comprehensive, well-designed PDMPs can serve a critical role in thwarting prescription drug abuse, as well as illegal drug diversion. It is essential for there to be broad access to PDMP data – by those with a legitimate purpose in such data – and as essential for PDMP programs to actively monitor their databases for suspicious activity, thereby providing a critical check on prescribers and dispensers and facilitating data-sharing.
Learning Objectives	1. State the basis for broad access to PDMP database, including third-party payers. 2. Identify specific strategies to avoid risky prescribing to help physicians avoid trouble with their Boards of the DEA. 3. Outline approaches to data-sharing among states.